| Malignant neoplasm of breast
Truqap vs Verzenio
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Truqap vs Verzenio with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVerzenio has a higher rate of injection site reactions vs Truqap based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Verzenio but not Truqap, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Truqap
Verzenio
At A Glance
Oral
Twice daily (4 days on, 3 days off)
AKT inhibitor
Oral
Twice daily
CDK4/6 inhibitor
Indications
- Malignant neoplasm of breast
- Malignant neoplasm of breast
- Carcinoma breast stage IV
Dosing
Malignant neoplasm of breast 400 mg orally twice daily (approximately 12 hours apart) with or without food, for 4 days followed by 3 days off, in combination with fulvestrant; continue until disease progression or unacceptable toxicity.
Malignant neoplasm of breast 150 mg orally twice daily in combination with tamoxifen or an aromatase inhibitor for 2 years as adjuvant treatment (or until disease recurrence or unacceptable toxicity).
Carcinoma breast stage IV 150 mg orally twice daily in combination with an aromatase inhibitor (initial therapy) or fulvestrant (after endocrine therapy progression); 200 mg orally twice daily as monotherapy (after endocrine therapy and prior chemotherapy); continue until disease progression or unacceptable toxicity.
Contraindications
- Severe hypersensitivity to capivasertib or any of its components
—
Adverse Reactions
Most common (>=20%) Diarrhea, cutaneous adverse reactions, increased random glucose, decreased lymphocytes, decreased hemoglobin, increased fasting glucose, nausea, fatigue, decreased leukocytes, increased triglycerides, decreased neutrophils, increased creatinine, vomiting, stomatitis
Serious Cutaneous adverse reactions, diarrhea, pneumonia, vomiting, pyrexia, hyperglycemia, hypersensitivity, fatigue, renal injury, second malignancy
Most common (>=20%) diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, alopecia, thrombocytopenia
Serious neutropenia, diarrhea, interstitial lung disease/pneumonitis, hepatotoxicity, venous thromboembolism
Postmarketing interstitial lung disease/pneumonitis
Pharmacology
Capivasertib is a pan-AKT inhibitor that blocks all three serine/threonine kinase AKT isoforms (AKT1, AKT2, AKT3), inhibiting phosphorylation of downstream AKT substrates and suppressing tumor growth driven by PIK3CA/AKT1/PTEN pathway alterations.
Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6); in ER-positive breast cancer cells, it blocks Rb phosphorylation and cell cycle progression from G1 into S phase, resulting in senescence and apoptosis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Truqap
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Verzenio
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Truqap
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Verzenio
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Truqap
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Verzenio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TruqapView full Truqap profile
VerzenioView full Verzenio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.